Ryuichi Mizuno
Overview
Explore the profile of Ryuichi Mizuno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
2177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shibata M, Umezawa A, Aoto S, Okamura K, Nasu M, Mizuno R, et al.
Regen Ther
. 2025 Feb;
28:431-437.
PMID: 39925965
The histological grading of carcinoma has been one of the central applications of task-specific deep learning in pathology. The deep learning method has pushed away the regression approach, which has...
2.
Iwasa S, Asanuma H, Takahashi R, Fukumoto K, Yasumizu Y, Tanaka N, et al.
Nihon Hinyokika Gakkai Zasshi
. 2025 Jan;
115(1):37-41.
PMID: 39828347
A 14-year-old boy developed hydronephrosis and worsening renal function due to fibroepithelial polyps of the bladder and left ureter at the age of 12 years. The endoscopic treatment of ureteral...
3.
Chung H, Kondoh C, Bae W, Tamada S, Matsubara N, Lee H, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39815637
Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in...
4.
Hayakawa N, Mizuno R, Tanaka T, Shiraishi Y, Matsumoto K, Kosaka T, et al.
Prostate Int
. 2024 Dec;
12(4):231-237.
PMID: 39735198
Introduction: Adverse events, such as erectile dysfunction (ED) and lower urinary tract symptoms (LUTS), are significant concerns in prostate cancer (PCa) patients treated with Iodine 125 (I-125) low-dose rate (LDR)...
5.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, et al.
Int J Clin Oncol
. 2024 Nov;
30(1):99-109.
PMID: 39549218
Background: Avelumab + axitinib was approved for advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world outcomes with first-line avelumab + axitinib from the J-DART2...
6.
Kikuchi E, Yamamoto H, Yasui T, Hatakeyama S, Mizuno R, Sakamoto S, et al.
Int J Urol
. 2024 Aug;
31(12):1344-1355.
PMID: 39154336
Objectives: The National Clinical Database (NCD) Urology Division commenced registration in April 2018 in Japan. This is the first report to focus on five surgeries for which detailed information is...
7.
Yasui T, Kikuchi E, Yamamoto H, Ishii D, Mizuno R, Hatakeyama S, et al.
Int J Urol
. 2024 Aug;
31(11):1256-1262.
PMID: 39105577
Background: The Japanese National Clinical Database (NCD) is a large-scale, nationwide, web-based data entry system that covers the majority of surgical cases performed in Japan. An NCD specializing in urological...
8.
Kaneko Y, Masuda T, Takamatsu K, Mikami S, Nakamura K, Nishihara H, et al.
J Pathol Clin Res
. 2024 Jun;
10(4):e12388.
PMID: 38923836
Tumor structure is heterogeneous and complex, and it is difficult to obtain complete characteristics by two-dimensional analysis. The aim of this study was to visualize and characterize volumetric vascular information...
9.
Matsumoto K, Kosaka T, Takeda T, Fukumoto K, Yasumizu Y, Tanaka N, et al.
Int J Clin Oncol
. 2024 Jun;
29(8):1198-1203.
PMID: 38856798
Background: Defined by rising PSA levels under androgen deprivation therapy (ADT) despite no visible metastases on conventional imaging, non-metastatic castration-resistant prostate cancer (nmCRPC) represents a complex clinical challenge. A significant...
10.
Yamashita R, Nakamura M, Notsu A, Asakura K, Usui K, Sakura Y, et al.
BJUI Compass
. 2024 May;
5(5):483-489.
PMID: 38751952
Objectives: This study aimed to evaluate the cumulative incidence of upper tract urothelial carcinoma (UTUC) recurrence and identify its risk factors in patients who underwent radical cystectomy (RC). Patients And...